Evidence map›Paper›PMID 42584156›Full record

ArticleMicrobiology spectrum2026

Development of an mRNA vaccine against the OprF of

Masoumeh Fathi, Lida Lotfollahi, Fatemeh Mehravar, Bizhan Nomanpour

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Masoumeh FathiDepartment of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0009-0006-4769-1939
Lida LotfollahiDepartment of Microbiology and Virology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.ORCID 0000-0002-3522-7104
Fatemeh MehravarDepartment of Public Health, Golestan University of medical Science, Gorgan, Iran.ORCID 0000-0002-4732-8519
Bizhan NomanpourDepartment of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.ORCID 0000-0002-0338-0171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, antibiotic resistance has been recognized as a major threat to global public health. IMPORTANCE: This work is one of the suitable mRNA-LNP vaccine designs because it targets an important immunogenic antigen that can induce both humoral and adaptive immunity against bacteria. As the first project of mRNA vaccine, especially for a non-viral microorganism in Iran, our results demonstrate good humoral immunity Induced by the vaccine developed against

Indexed as

Bacterial ProteinsPorinsPseudomonas aeruginosaPseudomonas InfectionsPseudomonas VaccinesRNA, MessengerAnimalsAntibodies, BacterialAntibodies, NeutralizingAntibody FormationFemaleLiposomesMiceMice, Inbred BALB CmRNA VaccinesNanoparticlesAntibodies, BacterialAntibodies, NeutralizingBacterial ProteinsLipid NanoparticlesLiposomesmRNA VaccinesOprF protein, Pseudomonas aeruginosaPorinsPseudomonas VaccinesRNA, Messengerantibiotic resistancelipid nanoparticlesmRNA vaccinePseudomonas aeruginosa

Identifiers

PMID42584156
PMCPMC13532285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.